Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.36T
24h Vol:
$8.60B
Dominance:
MSFT:4.78%
Stocklytics Platform
Instrument logo  ALVO
Alvotech
ALVO
48 / 100
$14.15arrow_drop_up3.66%$0.50

Performance History

Stocklytics logo
Key Stats
Open$14.00
Prev. Close$13.65
EPS-2.43
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.74B
PE Ratio-
LOWHIGH
Day Range14.00
14.23
52 Week Range6.70
18.00
Ratios
P/B Ratio0.00
Revenue$91.43M
Operating M. %-134.68%
Earnings$0.00
Earnings Growth %-7.43%
EBITDA Margin %-348.88%
ROE %0.00%
EPS-2.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

48vs 55. Market Avg.

All Score 48 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ALVOMARKET
Value3140
Quality3040
Ownership3417
Growth5543
Dividends-38
check_circle

Alvotech's Price growth average in the last 3 years of 41.36% is great compared to market average of 6.11%. This indicates ALVO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$733.51
24H (%)arrow_drop_up1.19%
24H ($)$8.64
MARKET CAP$695.32B
PRICE$495.35
24H (%)arrow_drop_up0.30%
24H ($)$1.49
MARKET CAP$454.39B
PRICE$146.14
24H (%)arrow_drop_down0.46%
24H ($)-$0.68
MARKET CAP$353.00B
PRICE$131.20
24H (%)arrow_drop_up0.36%
24H ($)$0.48
MARKET CAP$321.39B

About Alvotech (ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Mr. Robert Wessman
Headquarters
Reykjavik
Employees
917
Exchange
NASDAQ
add Alvotech to watchlist

Keep an eye on Alvotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Alvotech's (ALVO) price per share?

The current price per share for Alvotech (ALVO) is $14.15. The stock has seen a price change of $0.5 recently, indicating a 3.66% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Alvotech (ALVO)?

For Alvotech (ALVO), the 52-week high is $18, which is 27.21% from the current price. The 52-week low is $6.7, the current price is 111.19% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Alvotech (ALVO) a growth stock?

Alvotech (ALVO) has shown an average price growth of 52.31% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alvotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Alvotech (ALVO) stock price performance year to date (YTD)?

As of the latest data, Alvotech (ALVO) has a year-to-date price change of 24.56%. Over the past month, the stock has experienced a price change of 13.2%. Over the last three months, the change has been -3.41%. Over the past six months, the figure is 65.5%.

help
Is Alvotech (ALVO) a profitable company?

Alvotech (ALVO) has a net income of -$551.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -134.68% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $91.43M, with a revenue growth rate of 10.12%, providing insight into the company's sales performance and growth. Operating income is noted at -$354.86M. Furthermore, the EBITDA is -$318.99M.

help
What is the market capitalization of Alvotech (ALVO)?

Alvotech (ALVO) has a market capitalization of $3.75B. The average daily trading volume is 339.68K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.